Your browser doesn't support javascript.
loading
High occurrence of CRLF2 abnormalities in Mexican children with B-cell acute lymphoblastic leukemia.
Juárez-Velázquez, María Del Rocío; Moreno-Lorenzana, Dafné Linda; Martínez Anaya, Daniel Alejandro; Hernández Monterde, Eduardo Adrián; Aguilar-Hernández, María Montserrat; Reyes-León, Adriana; Chávez-González, María Antonieta; López Santiago, Norma; Zapata Tarrés, Marta; Juárez Villegas, Luis; Rivera Sánchez, Netzi; Soto Lerma, Oscar; Vega-Vega, Lourdes; Rivera Luna, Roberto; Pérez-Vera, Patricia.
Afiliação
  • Juárez-Velázquez MDR; Laboratorio de Genética y Cáncer, Instituto Nacional de Pediatría, Mexico City, Mexico.
  • Moreno-Lorenzana DL; Laboratorio de Genética y Cáncer, Instituto Nacional de Pediatría, Mexico City, Mexico; CONACYT-Instituto Nacional de Pediatría, Mexico City, Mexico.
  • Martínez Anaya DA; Laboratorio de Genética y Cáncer, Instituto Nacional de Pediatría, Mexico City, Mexico; Posgrado en Ciencias Biológicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.
  • Hernández Monterde EA; Laboratorio de Genética y Cáncer, Instituto Nacional de Pediatría, Mexico City, Mexico.
  • Aguilar-Hernández MM; Laboratorio de Genética y Cáncer, Instituto Nacional de Pediatría, Mexico City, Mexico; CONACYT-Instituto Nacional de Pediatría, Mexico City, Mexico.
  • Reyes-León A; Laboratorio de Genética y Cáncer, Instituto Nacional de Pediatría, Mexico City, Mexico.
  • Chávez-González MA; Unidad de Investigación Médica en Enfermedades Oncológicas, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
  • López Santiago N; Servicio de Hematología, Instituto Nacional de Pediatría, Mexico City, Mexico.
  • Zapata Tarrés M; Coordinación de Investigación, Fundación IMSS, A.C, Mexico City, Mexico.
  • Juárez Villegas L; Servicio de Hemato-Oncología, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.
  • Rivera Sánchez N; Laboratorio de Genética Molecular, Hospital Infantil Teletón de Oncología, Querétaro, México.
  • Soto Lerma O; Laboratorio de Genética y Cáncer, Instituto Nacional de Pediatría, Mexico City, Mexico; Becario de la Dirección General de Calidad y Educación en Salud, Secretaría de Salud México, Mexico.
  • Vega-Vega L; Dirección General, Hospital Infantil Teletón de Oncología, Querétaro, México.
  • Rivera Luna R; Jefatura de Radioterapia, Instituto Nacional de Pediatría, Mexico City, Mexico.
  • Pérez-Vera P; Laboratorio de Genética y Cáncer, Instituto Nacional de Pediatría, Mexico City, Mexico. Electronic address: sperezv@pediatria.gob.mx.
Cytokine ; 155: 155896, 2022 07.
Article em En | MEDLINE | ID: mdl-35537330
ABSTRACT
The P2RY8-CRLF2 and IGH-CRLF2 rearrangements induce the overexpression of cytokine receptor-like factor 2 (CRLF2) and have been associated with relapse and poor prognosis in B-cell acute lymphoblastic leukemia (B-ALL). Additionally, they are frequently documented in high-risk Hispanic populations. To better understand the potential causes of the adverse prognosis of childhood B-ALL in Mexico, we analyzed these rearrangements and the CRLF2 mRNA and protein levels in 133 Mexican children with B-ALL. We collected bone marrow samples at diagnosis and evaluated the CRLF2 gene expression by qRT-PCR and the total CRLF2 protein by flow cytometry. P2RY8-CRLF2 and IGH-CRLF2 were detected by RT-PCR and FISH, respectively. The median time of follow-up to determine the prognostic significance of the CRLF2 abnormalities was three years. In 82% of the participants, the mRNA levels correlated with the cell-surface and intracellular CRLF2 protein levels. The P2RY8-CRLF2 rearrangement was present in 31.5% (42/133) of the patients, while the IGH-CRLF2 rearrangement was detected in 13.5% (9/67) of patients with high expression of CRLF2 (6.8% of the total sample). CRLF2 copy number variations (gain) were also detected in 7.5% (5/67) of patients with high protein levels. The overall survival (OS) presented significantly lower rates in patients with high white blood cell count (≥50x109/L) regardless of CRLF2 expression, but high levels of CRLF2 gene expression appears to contribute to the reduction of OS within this group of patients. In conclusion, in our cohort, a high occurrence of CRLF2 abnormalities was documented, particularly the P2RY8-CRLF2 rearrangement, which might represent a characteristic of the Mexican population. Targeted therapy to treat this group of patients could improve OS.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras B / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans País/Região como assunto: Mexico Idioma: En Revista: Cytokine Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: México

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras B / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans País/Região como assunto: Mexico Idioma: En Revista: Cytokine Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: México